The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an oral presentation ...

FDA issued Complete Response Letter <li /> Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in ...